NCT05242874View on ClinicalTrials.gov

Anti-emetic Prophylaxis With or Without Dexamethasone

PHASE3CompletedINTERVENTIONAL
Enrollment

442

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen

Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.

DRUG

Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen

Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.

Trial Locations (2)

450008

Henan cacer hospital, Henan

Unknown

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV